Laboratory Corp American Holdings is a leading global life sciences company that offers comprehensive laboratory services, including diagnostic testing and drug development support. They operate advanced clinical laboratories that conduct a wide array of tests, specializing in areas such as genetics, infectious diseases, and routine screenings. The company also provides end-to-end solutions for the pharmaceutical and biotechnology industries, assisting in the development of new therapies and drugs through clinical trial testing and regulatory support. By leveraging cutting-edge technology and a vast network of resources, Laboratory Corp aims to improve healthcare outcomes and enhance patient care through accurate and timely laboratory results. Read More
Many investors pay attention to mid-cap stocks because they have established business models and expansive market opportunities.
However, their paths to becoming $100 billion corporations are ripe with competition, ranging from giants with vast resources to agile upstarts eager to disrupt the status quo.
The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how Labcorp (NYSE:LH) and the rest of the testing & diagnostics services stocks fared in Q2.
The stocks featured in this article have all approached their 52-week highs.
When these price levels hit, it typically signals strong business execution, positive market sentiment, or significant industry tailwinds.
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory destocking have harmed the industry’s returns -
over the past six months, healthcare stocks have collectively shed 14.2%. This drawdown is a noticeable divergence from the S&P 500’s 5.4% return.
Healthcare diagnostics company Labcorp Holdings (NYSE:LH) reported Q2 CY2025 results exceeding the market’s revenue expectations, with sales up 9.5% year on year to $3.53 billion. Its non-GAAP profit of $4.35 per share was 4.5% above analysts’ consensus estimates.
Curious about the top performers within the S&P500 index one hour before the close of the markets on Thursday? Dive into the list of today's session's top gainers and losers for a comprehensive overview.
Shares of healthcare diagnostics company Labcorp Holdings (NYSE:LH)
jumped 6.8% in the afternoon session after the company reported second-quarter earnings that beat analyst expectations and raised its full-year financial outlook. The laboratory network operator posted an adjusted EPS of $4.35, which surpassed consensus estimates. Revenue for the quarter increased 9.5% year-over-year to $3.53 billion, driven by growth in both its Diagnostics and Biopharma segments. In a significant show of confidence, Labcorp boosted its full-year 2025 guidance, projecting adjusted earnings per share between $16.05 and $16.50 and revenue growth between 7.5% and 8.6%. The company also noted that it had repurchased $200 million of its common stock during the quarter, further underscoring the strength of its financial position and business performance.
Let's take a look at the S&P500 stocks that are experiencing notable price gaps in today's session on Thursday. Discover the gap up and gap down stocks in the S&P500 index.
Healthcare diagnostics company Labcorp Holdings (NYSE:LH) announced better-than-expected revenue in Q2 CY2025, with sales up 9.5% year on year to $3.53 billion. Its non-GAAP profit of $4.35 per share was 4.5% above analysts’ consensus estimates.
